Laura Joszt, MA

Laura Joszt headshot

Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including Population Health, Equity & Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars®. She has been working on AJMC since 2014 and has been with AJMC’s parent company, MJH Life Sciences®, since 2011.

She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.

Articles by Laura Joszt, MA

After mentioning it for months, President Donald Trump has officially decided to stop paying the cost-sharing reduction subsidies that help insurers keep premiums down for lower-income Americans.

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers-from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.

The FDA has rejected an abuse-deterrent opioid citing the need for further evidence. Rexista, an Oxycodone Hydrochloride Extended-Release tablet (Oxycodone ER), was developed by Intellipharmaceutics International Inc as an abuse- and alcohol-deterrent controlled-release oral formulation of oxycodone hydrochloride for pain relief.

Most emergency department (ED) visits may not be as preventable as once thought. A new study in the International Journal for Quality in Health Care pointed out that while some estimates of "avoidable" ED visits have run anywhere between 4.8% and 90%, the reality is even lower.

The assumption in the United States is that once someone with cancer is cured, done with treatment, and healthy, that they are now okay. However, the reality is that survivors contend with lingering challenges that aren’t visible and make it difficult for them to ask for help or admit they need it.

Psoriasis severity has been linked to increased risk of death in a new study published in the Journal of Investigative Dermatology. Researchers found that the risk of death increased for patients who had more surface area covered by psoriasis.

Rivaroxaban plus aspirin has significant benefits for patients with peripheral artery disease (PAD) and stable coronary artery disease, according to the results of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial, presented at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.

A free-market system with competition should lead to reduced prices and savings-theoretically. In the case of healthcare, being able to shop around for the best priced service or product not only isn’t easy, but isn't always feasible.



Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo